Latest Breaking News On - Breyanzi priority medicines - Page 1 : comparemela.com

Global biopharmaceutical company Bristol Myers Squibb (BMS) has received  US Food and Drug Administration (USFDA) approval for its new CD19-directed chimeric antigen receptor (CAR) T cell therapy Breyanzi (lisocabtagene maraleucel; liso-cel).

United statesMeghan gutierrezSamit hirawatBristol myers squibbEuropean unionEuropean medicines agencyDrug administrationLymphoma research foundationMyers squibbRisk evaluationMitigation strategyCell therapyResearch foundationBreyanzi priority medicinesMarketing authorization applicationஒன்றுபட்டது மாநிலங்களில்